Early Lynch Syndrome Detection Saves
DiagMMMR is an accurate and precise functional test to detect Lynch syndrome, empowering individuals to take proactive steps for their health. Early detection means early intervention, leading to fewer hospital visits, fewer treatments, and, ultimately, lower healthcare costs for all.
The lifetime cost
of Lynch syndrome
A Lynch syndrome diagnosis puts patients on a proven path of screenings, prevention measures, and beneficial lifestyle changes. By covering the cost of Lynsight’s functional test today, you can save a lifetime of costs associated with overscreening and late-stage cancer treatments.
The rate of advanced disease is X percent lower when patients catch tumors early. By knowing if they have Lynch syndrome or not, patients can make lifestyle changes and get screened at an appropriate cadence to catch cancer before it progresses.
The total annual medical cost of colorectal cancer care in 2020 was
$24.3 BILLION
The lifetime cost of years of cancer treatments is
$XXX,XXX
Individuals who don’t have Lynch syndrome can save from years of overscreening.
The cost of multiple rounds of testing, interpretations, and doctor visits is
$XXX,XXX
Patented in 29 countries
Canada
United States
Brazil
Europe
China
Japan
Australia
FAQs
for payers
How does DiagMMR help in the detection of Lynch syndrome?
DiagMMR is an innovative diagnostics tool that accurately and precisely tests for Lynch syndrome by analyzing specific genetic markers associated with the condition. This advanced testing method allows for early detection, enabling timely intervention and potentially reducing long-term healthcare costs.
What are the potential cost savings associated with early detection of Lynch syndrome?
Early detection of Lynch syndrome through DiagMMR testing can lead to significant cost savings for all. By identifying individuals at risk early on, proactive measures can be taken to prevent the development or progression of associated cancers, which will reduce the need for expensive treatments and hospitalizations.
How does investing in DiagMMR testing align with cost-effective healthcare strategies?
Investing in DiagMMR testing aligns with cost-effective healthcare strategies by focusing on preventive care rather than reactive treatment. By detecting Lynch syndrome early and implementing appropriate interventions, we can reduce the overall financial burden associated with managing advanced cancer stages.
What are the potential implications of not covering DiagMMR testing for Lynch syndrome?
Not covering DiagMMR testing for Lynch syndrome may result in missed opportunities for early detection and prevention of associated cancers, leading to higher healthcare costs associated with advanced-stage cancer treatment and management. By covering DiagMMR testing, payers can mitigate these risks and promote cost-effective healthcare delivery.